These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
605 related articles for article (PubMed ID: 18535873)
21. Usefulness of somatostatin receptor scintigraphy in patients with occult ectopic adrenocorticotropin syndrome. Tabarin A; Valli N; Chanson P; Bachelot Y; Rohmer V; Bex-Bachellerie V; Catargi B; Roger P; Laurent F J Clin Endocrinol Metab; 1999 Apr; 84(4):1193-202. PubMed ID: 10199752 [TBL] [Abstract][Full Text] [Related]
22. Scintigraphic detection of carcinoid tumors with a cost effectiveness analysis. Dimitroulopoulos D; Xynopoulos D; Tsamakidis K; Paraskevas E; Zisimopoulos A; Andriotis E; Fotopoulou E; Kontis M; Paraskevas I World J Gastroenterol; 2004 Dec; 10(24):3628-33. PubMed ID: 15534919 [TBL] [Abstract][Full Text] [Related]
23. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Schillaci O; Corleto VD; Annibale B; Scopinaro F; Delle Fave G Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S186-9. PubMed ID: 10604127 [TBL] [Abstract][Full Text] [Related]
24. Prognostic clinicopathologic factors in longitudinally followed patients with metastatic small bowel carcinoid tumors. Curran T; Tulin-Silver S; Patel K; Ward S; Schneiderman M; Harpaz N; Schwartz M; Itzkowitz S; Warner RR; Kim MK Pancreas; 2011 Nov; 40(8):1253-7. PubMed ID: 21975435 [TBL] [Abstract][Full Text] [Related]
25. Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. Gibril F; Reynolds JC; Lubensky IA; Roy PK; Peghini PL; Doppman JL; Jensen RT J Nucl Med; 2000 Oct; 41(10):1646-56. PubMed ID: 11037994 [TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptor scintigraphy in metastatic breast cancer patients. Mezi S; Primi F; Orsi E; Capoccetti F; Scopinaro F; Schillaci O Oncol Rep; 2005 Jan; 13(1):31-5. PubMed ID: 15583798 [TBL] [Abstract][Full Text] [Related]
27. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience. Hubalewska-Dydejczyk A; Fröss-Baron K; Mikołajczak R; Maecke HR; Huszno B; Pach D; Sowa-Staszczak A; Janota B; Szybiński P; Kulig J Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1123-33. PubMed ID: 16721571 [TBL] [Abstract][Full Text] [Related]
28. The usefulness of 99mTc-tetrofosmin SPECT in the detection of lung metastases from extrapulmonary primary tumors. Spanu A; Solinas ME; Farris A; Arru A; Chessa F; Madeddu G; Falchi A; Madeddu G Radiol Med; 2004; 107(1-2):113-27. PubMed ID: 15031703 [TBL] [Abstract][Full Text] [Related]
29. Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Seregni E; Ferrari L; Bajetta E; Martinetti A; Bombardieri E Ann Oncol; 2001; 12 Suppl 2():S69-72. PubMed ID: 11762355 [TBL] [Abstract][Full Text] [Related]
30. Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Kidd M; Modlin IM; Mane SM; Camp RL; Shapiro MD Ann Surg; 2006 Feb; 243(2):273-80. PubMed ID: 16432362 [TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study. Dörr U; Würstlin S; Frank-Raue K; Raue F; Hehrmann R; Iser G; Scholz M; Guhl L; Buhr HJ; Bihl H Horm Metab Res Suppl; 1993; 27():48-55. PubMed ID: 8330872 [TBL] [Abstract][Full Text] [Related]
32. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors. Hoegerle S; Altehoefer C; Ghanem N; Koehler G; Waller CF; Scheruebl H; Moser E; Nitzsche E Radiology; 2001 Aug; 220(2):373-80. PubMed ID: 11477239 [TBL] [Abstract][Full Text] [Related]
33. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344 [TBL] [Abstract][Full Text] [Related]
34. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665 [TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Gibril F; Jensen RT Yale J Biol Med; 1997; 70(5-6):509-22. PubMed ID: 9825478 [TBL] [Abstract][Full Text] [Related]
36. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670 [TBL] [Abstract][Full Text] [Related]
37. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors. Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995 [TBL] [Abstract][Full Text] [Related]
38. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177 [TBL] [Abstract][Full Text] [Related]